Scancell Holdings plc (SCNLF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$1.41 (+0.00%) as of
Key statistics
- Market cap
- 1.91B
- EPS (TTM)
- -0.2300
- Dividend yield
- 0.00%
- 52-week range
- 0.1410 – 3.3487
- Beta
- 0.69
- Profit margin
- 0.00%
- Volume
- 15.00k
About Scancell Holdings plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oxford, United Kingdom
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.